Navigation Links
Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute

KENILWORTH, N.J., Feb. 8 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced leadership and organizational changes at Schering-Plough Research Institute (SPRI), the research and development arm of Schering-Plough.

Jacqueline Elbonne, Ph.D., has been named vice president, Global Research Quality, SPRI, effective immediately. In this position, Elbonne will build and lead a worldwide research quality team overseeing all SPRI activities governed by current Good Manufacturing Practices, Good Laboratory Practices, Good Clinical Practices and Good Pharmacovigilance Practices. In addition, she will direct and govern the design, implementation and performance management of global research Quality Management Systems to meet regulatory requirements and expectations worldwide. Elbonne will report directly to Thomas P. Koestler, Ph.D., executive vice president and president of SPRI, with shared accountability for SPRI quality systems to Richard S. Bowles III, senior vice president, Global Quality Operations.

Elbonne joined Schering-Plough in 2000 and has since held various positions of increasing responsibility in SPRI, Analytical Development and Global Quality. She recently served as vice president, Pharmaceutical Sciences Quality, providing quality leadership overseeing global clinical manufacturing operations, which included meeting all commitments under the U.S. consent decree. She earned a Ph.D. in organic chemistry and a Bachelor of Science degree in chemistry and pharmacology from the University of Liverpool, England.

The following new positions were created in response to the company's expanded product portfolio following the acquisition of Organon BioSciences. Effective immediately, Martin H. Huber, Jr., M.D., and Hans Rekers, M.D., will report to Robert J. Spiegel, M.D., chief medical officer and senior vice president. Huber is appointed vice president, Global Pharmacovigilance, and deputy chief medical officer. In this role, he will continue his current responsibilities and additionally will serve on Schering-Plough's Safety Review Board. He will also interact on product-related issues with health authorities and professional societies, manage medical aspects of litigation issues and work with medical directors from country operations on risk management and product-specific issues.

Huber has served as vice president, Global Pharmacovigilance, since joining Schering-Plough in July of 2006. He has played a key role in the development of a globally-aligned organization for Global Pharmacovigilance as part of Schering-Plough's Global Clinical Harmonization program and on the design and rollout of a rigorous computerized system for the collection, tracking and reporting of drug safety information. Huber received an M.D. degree from Baylor College of Medicine and a Bachelor of Science degree from Texas Lutheran College.

Hans Rekers, M.D., is appointed deputy chief medical officer for Europe. In this role, Rekers will continue his current responsibilities and additionally will serve on Schering-Plough's Safety Review Board and on the company's PReP (preparedness response) team. He will also interact on product- related issues with worldwide health authorities and professional societies, manage medical aspects of litigation issues and work with medical directors from country operations on risk management and product-specific issues.

Rekers has been with Organon International for the past 20 years serving in a range of positions of increasing responsibility, most recently as vice president, Medical Affairs. In this role, he has global oversight for the gynecological product portfolio. Rekers holds an M.D. from the University of Amsterdam.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
2. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
3. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
4. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
5. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Completes Acquisition of Organon BioSciences
8. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
9. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
10. Schering-Plough Announces Pricing of Senior Notes Offering
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):